2nd TRP Target Selection & Drug Design Summit, Feb 21-24, 2026 in Boston, US
[…]
Fighting Cancer with Precision
Powered by PreTarg-it®:
the platform for next-generation pretargeted radioimmunotherapies.
Target First. Treat with Precision.
Targeted radionuclide therapies offer significant potential in precision oncology, but their clinical impact is often limited by off-target radiation.
To address this challenge, PreTarg-it® applies a two-step pretargeted radioimmunotherapy strategy by first targeting the tumor and then delivering the radionuclide.
Step 1 – Targeting Phase
A tumor-targeting bispecific antibody is administered. It binds to cancer cells, accumulates in the tumor and clears from circulation.
Step 2 – Delivery Phase
A radiolabeled small ligand is introduced. It binds to the pre-positioned antibody, delivering a concentrated dose of radiation directly to the tumor.
This sequential approach is designed to improve tumor selectivity and enable more controlled radionuclide delivery, minimizing off-target exposure and enhancing therapeutic precision.
Structured for Precision. Built for Translation.
PreTarg-it® is a modular pretargeted radioimmunotherapy platform designed to achieve a high therapeutic index and rapid pharmacokinetics.
Our platform enables therapies tailored to specific tumor targets and supports the use of both therapeutic and diagnostic (theranostic) radionuclides across a range of oncologic indications.
Why PreTarg-it®?
Sequential Targeting
Sophisticated two-step strategy that separates tumor targeting from radionuclide delivery.
Scientific Rigor. Structured Innovation.
Our interdisciplinary team brings together expertise across antibody engineering, radiopharmaceutical development, translational oncology, and regulatory strategy.
Scientific Rigor. Structured Innovation.
Our interdisciplinary team brings together expertise across antibody engineering, radiopharmaceutical development, translational oncology, and regulatory strategy.
Partnership
Strategic Partnerships
Advance next-generation radiopharmaceuticals with OncoOne.
Collaborate with us to expand pretargeted radioimmunotherapy across new targets and indications through our adaptable PreTarg-it® platform.
| Public Grants
